Bengt Lindholm

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9225576/publications.pdf

Version: 2024-02-01

309 papers	16,164 citations	22153 59 h-index	20961 115 g-index
316 all docs	316 docs citations	316 times ranked	13217 citing authors

#	Article	IF	Citations
1	IL-10, IL-6, and TNF-Î±: Central factors in the altered cytokine network of uremiaâ€"The good, the bad, and the ugly. Kidney International, 2005, 67, 1216-1233.	5.2	738
2	Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrology Dialysis Transplantation, 2000, 15, 953-960.	0.7	701
3	Factors predicting malnutrition in hemodialysis patients: A cross-sectional study. Kidney International, 1998, 53, 773-782.	5.2	507
4	The malnutrition, inflammation, and atherosclerosis (MIA) syndrome - the heart of the matter. Nephrology Dialysis Transplantation, 2002, 17, 28-31.	0.7	473
5	Emerging Biomarkers for Evaluating Cardiovascular Risk in the Chronic Kidney Disease Patient. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 505-521.	4.5	472
6	Serum Albumin, C-Reactive Protein, Interleukin 6, and Fetuin A as Predictors of Malnutrition, Cardiovascular Disease, and Mortality in Patients With ESRD. American Journal of Kidney Diseases, 2006, 47, 139-148.	1.9	442
7	Comparative Associations of Muscle Mass and Muscle Strength with Mortality in Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1720-1728.	4.5	386
8	Associations between circulating inflammatory markers and residual renal function in CRF patients. American Journal of Kidney Diseases, 2003, 41, 1212-1218.	1.9	371
9	Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrology Dialysis Transplantation, 2002, 17, 1684-1688.	0.7	345
10	Chronic inflammation in end-stage renal disease and dialysis. Nephrology Dialysis Transplantation, 2018, 33, iii35-iii40.	0.7	249
11	Obese sarcopenia in patients with end-stage renal disease is associated with inflammation and increased mortality. American Journal of Clinical Nutrition, 2007, 86, 633-638.	4.7	246
12	Sarcopenia in chronic kidney disease on conservative therapy: prevalence and association with mortality. Nephrology Dialysis Transplantation, 2015, 30, 1718-1725.	0.7	246
13	Serum Trimethylamine-N-Oxide Is Strongly Related to Renal Function and Predicts Outcome in Chronic Kidney Disease. PLoS ONE, 2016, 11, e0141738.	2.5	241
14	Muscle atrophy, inflammation and clinical outcome in incident and prevalent dialysis patients. Clinical Nutrition, 2008, 27, 557-564.	5.0	230
15	Pathophysiology of Peritoneal Membrane Failure. Peritoneal Dialysis International, 2000, 20, 22-42.	2.3	228
16	Consequences of low plasma histidine in chronic kidney disease patients: associations with inflammation, oxidative stress, and mortality. American Journal of Clinical Nutrition, 2008, 87, 1860-1866.	4.7	228
17	Global Prevalence of Protein-Energy Wasting in Kidney Disease: A Meta-analysis of Contemporary Observational Studies From the International Society of Renal Nutrition and Metabolism. , 2018, 28, 380-392.		225
18	J-Shaped Mortality Relationship for Uric Acid in CKD. American Journal of Kidney Diseases, 2006, 48, 761-771.	1.9	213

#	Article	IF	Citations
19	Coronary Artery Disease in End-Stage Renal Disease. Journal of the American Society of Nephrology: JASN, 2003, 14, 1927-1939.	6.1	208
20	Sarcopenia in chronic kidney disease: what have we learned so far?. Journal of Nephrology, 2021, 34, 1347-1372.	2.0	204
21	Comparison of nutritional and inflammatory markers in dialysis patients with reduced appetite. American Journal of Clinical Nutrition, 2007, 85, 695-701.	4.7	202
22	Screening for muscle wasting and dysfunction inÂpatients with chronic kidney disease. Kidney International, 2016, 90, 53-66.	5.2	199
23	A quantitative description of solute and fluid transport during peritoneal dialysis. Kidney International, 1992, 41, 1320-1332.	5.2	179
24	Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney International, 2000, 57, 1727-1735.	5.2	177
25	Increases in Serum Leptin Levels during Peritoneal Dialysis Are Associated with Inflammation and a Decrease in Lean Body Mass. Journal of the American Society of Nephrology: JASN, 2000, 11, 1303-1309.	6.1	168
26	Sex and gender differences in chronic kidney disease: progression to end-stage renal disease and haemodialysis. Clinical Science, 2016, 130, 1147-1163.	4.3	167
27	A comparative analysis of nutritional parameters as predictors of outcome in male and female ESRD patients. Nephrology Dialysis Transplantation, 2002, 17, 1266-1274.	0.7	166
28	Calculation of the Protein Equivalent of Total Nitrogen Appearance from Urea Appearance. Which Formulas Should be Used?. Peritoneal Dialysis International, 1998, 18, 467-473.	2.3	161
29	Biomarkers of Cardiovascular Disease and Mortality Risk in Patients with Advanced CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1163-1172.	4.5	133
30	Plasma Pentosidine Is Associated with Inflammation and Malnutrition in End-Stage Renal Disease Patients Starting on Dialysis Therapy. Journal of the American Society of Nephrology: JASN, 2003, 14, 1614-1622.	6.1	131
31	Homocysteine in uraemia--a puzzling and conflicting story. Nephrology Dialysis Transplantation, 2005, 20, 16-21.	0.7	130
32	Food as medicine: targeting the uraemic phenotype in chronic kidney disease. Nature Reviews Nephrology, 2021, 17, 153-171.	9.6	126
33	Mediterranean Diet, Kidney Function, and Mortality in Men with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1548-1555.	4.5	119
34	Abdominal fat deposition is associated with increased inflammation, protein-energy wasting and worse outcome in patients undergoing haemodialysis. Nephrology Dialysis Transplantation, 2010, 25, 562-568.	0.7	116
35	Association between residual renal function, inflammation and patient survival in new peritoneal dialysis patients. Nephrology Dialysis Transplantation, 2003, 18, 590-597.	0.7	115
36	Dietary Components That May Influence the Disturbed Gut Microbiota in Chronic Kidney Disease. Nutrients, 2019, 11, 496.	4.1	112

#	Article	IF	Citations
37	Associations between plasma ghrelin levels and body composition in end-stage renal disease: a longitudinal study. Nephrology Dialysis Transplantation, 2004, 19, 421-426.	0.7	110
38	Adipose tissue and its relation to inflammation: The role of adipokines. , 2005, 15, 131-136.		108
39	What Are the Causes and Consequences of the Chronic Inflammatory State in Chronic Dialysisâ€ƒPatients?. Seminars in Dialysis, 2000, 13, 163-164.	1.3	105
40	Albuminuria changes are associated with subsequent risk of end-stage renal disease andÂmortality. Kidney International, 2017, 91, 244-251.	5.2	104
41	Novel Links between the Long Pentraxin 3, Endothelial Dysfunction, and Albuminuria in Early and Advanced Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 976-985.	4.5	103
42	Increased circulating sclerostin levels in end-stage renal disease predict biopsy-verified vascular medial calcification and coronary artery calcification. Kidney International, 2015, 88, 1356-1364.	5.2	102
43	Influence of Peritoneal Transport Rate, Inflammation, and Fluid Removal on Nutritional Status and Clinical Outcome in Prevalent Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2003, 23, 174-183.	2.3	101
44	Dietary Fiber, Kidney Function, Inflammation, and Mortality Risk. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 2104-2110.	4.5	101
45	Systemic and Intraperitoneal Interleukin-6 System during the First Year of Peritoneal Dialysis. Peritoneal Dialysis International, 2006, 26, 53-63.	2.3	98
46	Serum Lipids and Lipoproteins during Continuous Ambulatory Peritoneal Dialysis. Acta Medica Scandinavica, 1986, 220, 143-151.	0.0	95
47	Therapeutics targeting persistent inflammation in chronic kidney disease. Translational Research, 2016, 167, 204-213.	5.0	92
48	The higher mortality associated with low serum albumin is dependent on systemic inflammation in end-stage kidney disease. PLoS ONE, 2018, 13, e0190410.	2.5	91
49	Chronic Inflammation in Peritoneal Dialysis: The Search for the Holy Grail?. Peritoneal Dialysis International, 2004, 24, 327-339.	2.3	90
50	Influence of Initial Nutritional Status on Continuous Ambulatory Peritoneal Dialysis Patient Survival. Peritoneal Dialysis International, 2000, 20, 19-26.	2.3	89
51	Peritoneal Transport Characteristics, Comorbid Diseases and Survival in CAPD Patients. Peritoneal Dialysis International, 2000, 20, 541-547.	2.3	88
52	ADMA Levels Correlate with Proteinuria, Secondary Amyloidosis, and Endothelial Dysfunction. Journal of the American Society of Nephrology: JASN, 2008, 19, 388-395.	6.1	84
53	Effect of Circulating Soluble Receptor for Advanced Glycation End Products (sRAGE) and the Proinflammatory RAGE Ligand (EN-RAGE, S100A12) on Mortality in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 2213-2219.	4.5	83
54	Body Fat Mass and Serum Leptin Levels Influence Epoetin Sensitivity in Patients With ESRD. American Journal of Kidney Diseases, 2005, 46, 628-634.	1.9	78

#	Article	IF	Citations
55	Soluble CD14 Levels, Interleukin 6, and Mortality Among Prevalent Hemodialysis Patients. American Journal of Kidney Diseases, 2009, 54, 1072-1080.	1.9	75
56	Simple Models for Description of Small-Solute Transport in Peritoneal Dialysis. Blood Purification, 1991, 9, 129-141.	1.8	74
57	Relation between serum fibroblast growth factor-23 level and mortality in incident dialysis patients: are gender and cardiovascular disease confounding the relationship?. Nephrology Dialysis Transplantation, 2010, 25, 3033-3038.	0.7	69
58	Association between an Increased Surface Area of Peritoneal Microvessels and a High Peritoneal Solute Transport Rate. Peritoneal Dialysis International, 2003, 23, 116-122.	2.3	65
59	Early Vascular Ageing and Cellular Senescence in Chronic Kidney Disease. Computational and Structural Biotechnology Journal, 2019, 17, 721-729.	4.1	65
60	Impact of curcumin supplementation on expression of inflammatory transcription factors in hemodialysis patients: A pilot randomized, double-blind, controlled study. Clinical Nutrition, 2020, 39, 3594-3600.	5.0	65
61	Does statins promote vascular calcification in chronic kidney disease?. European Journal of Clinical Investigation, 2017, 47, 137-148.	3.4	62
62	The reverse epidemiology of plasma total homocysteine as a mortality risk factor is related to the impact of wasting and inflammation. Nephrology Dialysis Transplantation, 2006, 22, 209-217.	0.7	61
63	Inflammation contributes to low plasma amino acid concentrations in patients with chronic kidney disease. American Journal of Clinical Nutrition, 2005, 82, 342-349.	4.7	60
64	Clinical global assessment of nutritional status as predictor of mortality in chronic kidney disease patients. PLoS ONE, 2017, 12, e0186659.	2.5	60
65	Red meat intake in chronic kidney disease patients: Two sides of the coin. Nutrition, 2018, 46, 26-32.	2.4	59
66	Lymphatic Absorption in CAPD Patients with Loss of Ultrafiltration Capacity. Blood Purification, 1995, 13, 327-339.	1.8	58
67	Elevated serum levels of S-adenosylhomocysteine, but not homocysteine, are associated with cardiovascular disease in stage 5 chronic kidney disease patients. Clinica Chimica Acta, 2008, 395, 106-110.	1.1	58
68	The dysfunctional endothelium in CKD and in cardiovascular disease: mapping the origin(s) of cardiovascular problems in CKD and of kidney disease in cardiovascular conditions for a research agenda. Kidney International Supplements, 2011, 1, 6-9.	14.2	57
69	Combination of Crystalloid (Glucose) and Colloid (Icodextrin) Osmotic Agents Markedly Enhances Peritoneal Fluid and Solute Transport during the Long PD Dwell. Peritoneal Dialysis International, 2007, 27, 267-276.	2.3	56
70	Chronic Systemic Inflammation in Dialysis Patients: An Update on Causes and Consequences. ASAIO Journal, 2004, 50, Iii-Ivii.	1.6	54
71	Diagnostic validation and prognostic significance of the Malnutrition-Inflammation Score in nondialyzed chronic kidney disease patients. Nephrology Dialysis Transplantation, 2015, 30, 821-828.	0.7	54
72	Curcumin - A promising nutritional strategy for chronic kidney disease patients. Journal of Functional Foods, 2018, 40, 715-721.	3.4	54

#	Article	IF	Citations
73	A Proinflammatory Diet Is Associated with Systemic Inflammation and Reduced Kidney Function in Elderly Adults. Journal of Nutrition, 2015, 145, 729-735.	2.9	53
74	Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease Stage 5 patients. Nephrology Dialysis Transplantation, 2015, 30, 84-91.	0.7	52
75	eGFR and the Risk of Community-Acquired Infections. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1399-1408.	4.5	52
76	Osmotic Conductance of the Peritoneum in Capd Patients with Permanent Loss of Ultrafiltration Capacity. Peritoneal Dialysis International, 1996, 16, 488-496.	2.3	50
77	Vascular calcification in chronic kidney disease: are biomarkers useful for probing the pathobiology and the health risks of this process in the clinical scenario?. Nephrology Dialysis Transplantation, 2014, 29, 1275-1284.	0.7	50
78	Clinical Correlates of Insulin Sensitivity and Its Association with Mortality among Men with CKD Stages 3 and 4. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 690-697.	4.5	50
79	Kidney Function, Kidney Function Decline, and the Risk of Dementia in Older Adults. Neurology, 2021, 96, .	1.1	50
80	Effect of blood perfusion on diffusive transport in peritoneal dialysis. Kidney International, 1999, 56, 707-713.	5.2	49
81	Modification of the oxidative stress biomarker AOPP assay: Application in uremic samples. Clinica Chimica Acta, 2008, 393, 114-118.	1.1	48
82	Diffusive Mass Transport Coefficients Are Not Constant During a Single Exchange In Continuous Ambulatory Peritoneal Dialysis. ASAIO Journal, 1996, 42, M518-523.	1.6	47
83	Overestimation of advanced oxidation protein products in uremic plasma due to presence of triglycerides and other endogenous factors. Clinica Chimica Acta, 2007, 379, 87-94.	1.1	47
84	The kidney is the major site of S-adenosylhomocysteine disposal in humans. Kidney International, 2009, 76, 293-296.	5.2	47
85	Mechanisms of Crystalloid versus Colloid Osmosis across the Peritoneal Membrane. Journal of the American Society of Nephrology: JASN, 2018, 29, 1875-1886.	6.1	47
86	Methods for Estimation of Peritoneal Dialysate Volume and Reabsorption Rate Using Macromolecular Markers. Peritoneal Dialysis International, 1994, 14, 8-16.	2.3	46
87	Estimated Glomerular Filtration Rate and the Risk of Cancer. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 530-539.	4.5	46
88	Impact of Residual Renal Function on Volume Status in Chronic Renal Failure. Blood Purification, 2004, 22, 285-292.	1.8	45
89	Enhanced scavenger receptor expression in monocyte-macrophages in dialysis patients. Kidney International, 1996, 49, 773-780.	5.2	44
90	Vibratory perception threshold compared with nerve conduction velocity in the evaluation of uremic neuropathy. Acta Neurologica Scandinavica, 1985, 71, 284-289.	2.1	44

#	Article	IF	Citations
91	Remote Patient Monitoring Program in Automated Peritoneal Dialysis: Impact on Hospitalizations. Peritoneal Dialysis International, 2019, 39, 472-478.	2.3	44
92	Biocompatibility of New Peritoneal Dialysis Solutions: Clinical Experience. Peritoneal Dialysis International, 2000, 20, 48-56.	2.3	43
93	Short-Term Effects of a New Bicarbonate/Lactate-Buffered and Conventional Peritoneal Dialysis Fluid on Peritoneal and Systemic Inflammation in CAPD Patients: A Randomized Controlled Study. Peritoneal Dialysis International, 2008, 28, 44-52.	2.3	43
94	Diffusive and Convective Solute Transport in Peritoneal Dialysis with Glucose as an Osmotic Agent. Artificial Organs, 1995, 19, 295-306.	1.9	42
95	Determination of High and Low Molecular Weight Molecules of Icodextrin in Plasma and Dialysate, Using Gel Filtration Chromatography, in Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2005, 25, 181-191.	2.3	42
96	Effect of repeated intravenous iron administration in haemodialysis patients on serum 8-hydroxy-2'-deoxyguanosine levels. Nephrology Dialysis Transplantation, 2007, 22, 1407-1412.	0.7	42
97	Risk factors for mortality in diabetic peritoneal dialysis patients. Nephrology Dialysis Transplantation, 2010, 25, 3742-3748.	0.7	42
98	Vertebral bone density associates with coronary artery calcification and is an independent predictor of poor outcome in end-stage renal disease patients. Bone, 2016, 92, 50-57.	2.9	42
99	Peritoneal Transport during Dialysis with Amino Acid-Based Solutions. Peritoneal Dialysis International, 1993, 13, 280-288.	2.3	40
100	Clinical importance of an elevated circulating chemerin level in incident dialysis patients. Nephrology Dialysis Transplantation, 2010, 25, 4017-4023.	0.7	40
101	Hyperhomocysteinemia in relation to plasma free amino acids, biomarkers of inflammation and mortality in patients with chronic kidney disease starting dialysis therapy. American Journal of Kidney Diseases, 2004, 44, 455-465.	1.9	38
102	Interleukin-6 Is a Better Predictor of Mortality as Compared to C-Reactive Protein, Homocysteine, Pentosidine and Advanced Oxidation Protein Products in Hemodialysis Patients. Blood Purification, 2008, 26, 204-210.	1.8	37
103	Circulating Follistatin in Patients with Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1001-1008.	4.5	37
104	Oxidative Dna Damage and Mortality in Hemodialysis and Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2015, 35, 206-215.	2.3	37
105	Elevated intracellular copper contributes a unique role to kidney fibrosis by lysyl oxidase mediated matrix crosslinking. Cell Death and Disease, 2020, 11, 211.	6.3	37
106	Validation of insulin sensitivity surrogate indices and prediction of clinical outcomes in individuals with and without impaired renal function. Kidney International, 2014, 86, 383-391.	5.2	36
107	Bone mineral density and mortality in end-stage renal disease patients. CKJ: Clinical Kidney Journal, 2020, 13, 307-321.	2.9	36
108	Paradoxes in Peritoneal Transport of Small Solutes. Peritoneal Dialysis International, 1996, 16, 63-70.	2.3	35

#	Article	IF	Citations
109	IGF-1 and Survival in ESRD. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 120-127.	4.5	34
110	Plasma Pentosidine and Its Association with Mortality in Patients with Chronic Kidney Disease. PLoS ONE, 2016, 11, e0163826.	2.5	34
111	Lung Dysfunction and Mortality in Patients with Chronic Kidney Disease. Kidney and Blood Pressure Research, 2018, 43, 522-535.	2.0	33
112	Health-related quality of life as predictor of mortality in end-stage renal disease patients: an observational study. BMC Nephrology, 2019, 20, 144.	1.8	33
113	Computer simulations of osmotic ultrafiltration and small-solute transport in peritoneal dialysis: a spatially distributed approach. American Journal of Physiology - Renal Physiology, 2012, 302, F1331-F1341.	2.7	32
114	Subclinical versus overt obesity in dialysis patients: more than meets the eye. Nephrology Dialysis Transplantation, 2013, 28, iv175-iv181.	0.7	32
115	The endothelin system as target for therapeutic interventions in cardiovascular and renal disease. Clinica Chimica Acta, 2020, 506, 92-106.	1.1	32
116	Nutritional status of older patients on hemodialysis: Which nutritional markers can best predict clinical outcomes?. Nutrition, 2019, 65, 113-119.	2.4	31
117	Uremic serum enhances scavenger receptor expression and activity in the human monocytic cell line U937. Kidney International, 1997, 51, 785-792.	5.2	29
118	Experimental Encapsulating Peritoneal Sclerosis Models: Pathogenesis and Treatment. Peritoneal Dialysis International, 2008, 28, 21-28.	2.3	29
119	Uremic Polyneuropathy: Different Effects of Hemodialysis and Continuous Ambulatory Peritoneal Dialysis. Acta Medica Scandinavica, 1985, 218, 409-416.	0.0	29
120	Muscle Water and Electrolytes in Patients Undergoing Continuous Ambulatory Peritoneal Dialysis. Acta Medica Scandinavica, 1986, 219, 323-330.	0.0	29
121	Changes in circulating biomarkers during a single hemodialysis session. Hemodialysis International, 2013, 17, 59-66.	0.9	29
122	Inflammation modifies the association of osteoprotegerin with mortality in chronic kidney disease. Journal of Nephrology, 2009, 22, 774-82.	2.0	29
123	Serum albumin, inflammation, and nutrition in endâ€stage renal disease: Câ€reactive protein is needed for optimal assessment. Seminars in Dialysis, 2018, 31, 435-439.	1.3	28
124	Cruciferous vegetables: rationale for exploring potential salutary effects of sulforaphane-rich foods in patients with chronic kidney disease. Nutrition Reviews, 2021, 79, 1204-1224.	5.8	28
125	Peritoneal Transport in Peritoneal Dialysis Patients Using Glucose-Based and Amino Acid-Based Solutions. Peritoneal Dialysis International, 2007, 27, 544-553.	2.3	27
126	How Accurate is the Description of Transport Kinetics in Peritoneal Dialysis According to Different Versions of the Three-Pore Model?. Peritoneal Dialysis International, 2008, 28, 53-60.	2.3	27

#	Article	IF	Citations
127	Definition of Metabolic Syndrome in Peritoneal Dialysis. Peritoneal Dialysis International, 2009, 29, 137-144.	2.3	27
128	Total and bone-specific alkaline phosphatase are associated with bone mineral density over time in end-stage renal disease patients starting dialysis. Journal of Nephrology, 2017, 30, 255-262.	2.0	27
129	Alterations of peritoneal transport characteristics in dialysis patients with ultrafiltration failure: tissue and capillary components. Nephrology Dialysis Transplantation, 2019, 34, 864-870.	0.7	27
130	Simple Membrane Models for Peritoneal Dialysis Evaluation of Diffusive and Convective Solute Transport. ASAIO Journal, 1992, 38, 788-796.	1.6	26
131	TOF-SIMS analysis of adipose tissue from patients with chronic kidney disease. Applied Surface Science, 2008, 255, 1177-1180.	6.1	26
132	Metabolic abnormalities in chronic kidney disease that contribute to cardiovascular disease, and nutritional initiatives that may diminish the risk. Current Opinion in Lipidology, 2009, 20, 3-9.	2.7	26
133	Cardiovascular Biomarkers in Chronic Kidney Disease. , 2012, 22, 120-127.		26
134	A real-world cohort study on the quality of potassium and creatinine monitoring during initiation of mineralocorticoid receptor antagonists in patients with heart failure. European Heart Journal Quality of Care & Clinical Outcomes, 2018, 4, 267-273.	4.0	26
135	Serum 8-hydroxydeoxyguanosine, a marker of oxidative DNA damage, is associated with mortality independent of inflammation in chronic kidney disease. European Journal of Internal Medicine, 2019, 68, 60-65.	2.2	25
136	Skin autofluorescence, arterial stiffness and Framingham risk score as predictors of clinical outcome in chronic kidney disease patients: a cohort study. Nephrology Dialysis Transplantation, 2019, 34, 442-448.	0.7	25
137	Icodextrin Metabolism and Alpha-Amylase Activity in Nonuremic Rats Undergoing Chronic Peritoneal Dialysis. Peritoneal Dialysis International, 2007, 27, 415-423.	2.3	24
138	The AGEâ€“RAGE Pathway and Its Relation to Cardiovascular Disease in Patients with Chronic Kidney Disease. Archives of Medical Research, 2013, 44, 601-610.	3.3	24
139	Effects of probiotic supplementation on inflammatory biomarkers and uremic toxins in non-dialysis chronic kidney patients: A double-blind, randomized, placebo-controlled trial. Journal of Functional Foods, 2018, 46, 378-383.	3.4	24
140	Hypoalbuminemia: a price worth paying for improved dialytic removal of middle-molecular-weight uremic toxins?. Nephrology Dialysis Transplantation, 2019, 34, 901-907.	0.7	24
141	Restrictive lung disorder is common in patients with kidney failure and associates with protein-energy wasting, inflammation and cardiovascular disease. PLoS ONE, 2018, 13, e0195585.	2.5	23
142	Nutritional status, hyperkalaemia and attainment of energy/protein intake targets in haemodialysis patients following plant-based diets: a longitudinal cohort study. Nephrology Dialysis Transplantation, 2021, 36, 681-688.	0.7	23
143	Bidirectional Solute Transport in Peritoneal Dialysis. Peritoneal Dialysis International, 1994, 14, 327-337.	2.3	22
144	Peritoneal Fluid Transport in CAPD Patients with Different Transport Rates of Small Solutes. Peritoneal Dialysis International, 2004, 24, 240-251.	2.3	22

#	Article	IF	Citations
145	Câ€reactive Protein: Repeated Measurements will Improve Dialysis Patient Care. Seminars in Dialysis, 2016, 29, 7-14.	1.3	22
146	A single session of haemodialysis improves left ventricular synchronicity in patients with end-stage renal disease: a pilot tissue synchronization imaging study. Nephrology Dialysis Transplantation, 2008, 23, 3622-3628.	0.7	21
147	Kinetic Analysis of Peritoneal Fluid and Solute Transport with Combination of Glucose and Icodextrin as Osmotic Agents. Peritoneal Dialysis International, 2009, 29, 72-80.	2.3	21
148	Bioactive food and exercise in chronic kidney disease: Targeting the mitochondria. European Journal of Clinical Investigation, 2018, 48, e13020.	3.4	21
149	Mitochondrial dysfunction and gut microbiota imbalance: An intriguing relationship in chronic kidney disease. Mitochondrion, 2019, 47, 206-209.	3.4	21
150	The influence of hepatitis C and iron replacement therapy on plasma pentosidine levels in haemodialysis patients. Nephrology Dialysis Transplantation, 2004, 19, 3112-3116.	0.7	20
151	Timing of Dialysis Initiation: When to Start? Which Treatment?. , 2015, 25, 238-241.		20
152	Thyroid Function Test Derangements and Mortality in Dialysis Patients: A Systematic Review and Meta-analysis. American Journal of Kidney Diseases, 2016, 68, 923-932.	1.9	20
153	Chronic kidney disease is associated with poorer in-hospital outcomes in patients hospitalized with infections: Electronic record analysis from China. Scientific Reports, 2017, 7, 11530.	3.3	20
154	Healthâ€related quality of life in peritoneal dialysis patients: A narrative review. Seminars in Dialysis, 2019, 32, 452-462.	1.3	20
155	Inverse J-shaped relation between coronary arterial calcium density and mortality in advanced chronic kidney disease. Nephrology Dialysis Transplantation, 2020, 35, 1202-1211.	0.7	20
156	Bone mineral density at different sites and 5 years mortality in end-stage renal disease patients: A cohort study. Bone, 2020, 130, 115075.	2.9	20
157	Glucose Tolerance in Patients Undergoing Continuous Ambulatory Peritoneal Dialysis. Acta Medica Scandinavica, 1986, 220, 477-483.	0.0	19
158	Changes in Free Water Fraction and Aquaporin Function With Dwell Time During Continuous Ambulatory Peritoneal Dialysis. Artificial Organs, 2010, 34, 1138-1143.	1.9	19
159	Increased Levels of Modified Advanced Oxidation Protein Products are Associated with Central and Peripheral Blood Pressure in Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2015, 35, 460-470.	2.3	19
160	Offering Patients Therapy Options in Unplanned Start (OPTiONS): Implementation of an educational program is feasible and effective. BMC Nephrology, 2017, 18, 18.	1.8	19
161	Modelling Transcapillary Transport of Fluid and Proteins in Hemodialysis Patients. PLoS ONE, 2016, 11, e0159748.	2.5	19
162	The Effect of Dialysate Acidity on Peritoneal Solute Transport in the Rat. Peritoneal Dialysis International, 1995, 15, 312-319.	2.3	18

#	Article	IF	Citations
163	CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: Homocysteineâ€Lowering Is Not a Primary Target for Cardiovascular Disease Prevention in Chronic Kidney Disease Patients. Seminars in Dialysis, 2007, 20, 523-529.	1.3	18
164	Association of Kidney Function with Infections by Multidrug-Resistant Organisms: An Electronic Medical Record Analysis. Scientific Reports, 2018, 8, 13372.	3.3	18
165	Fractures after kidney transplantation: Incidence, predictors, and association with mortality. Bone, 2020, 140, 115554.	2.9	18
166	Plant-based diets, insulin sensitivity and inflammation in elderly men with chronic kidney disease. Journal of Nephrology, 2020, 33, 1091-1101.	2.0	18
167	Role of Uremic Toxins in Early Vascular Ageing and Calcification. Toxins, 2021, 13, 26.	3.4	18
168	Osteoprotegerin is a marker of cardiovascularÂmortalityÂin patients with chronic kidney disease stages 3â€“5. Scientific Reports, 2021, 11, 2473.	3.3	18
169	Hypogonadism associated with muscle atrophy, physical inactivity and ESA hyporesponsiveness in men undergoing haemodialysis. Nefrologia, 2017, 37, 54-60.	0.4	17
170	Methyl Donor Nutrients in Chronic Kidney Disease: Impact on the Epigenetic Landscape. Journal of Nutrition, 2019, 149, 372-380.	2.9	17
171	A Comparative Analysis of Nutritional Assessment Using Global Leadership Initiative on Malnutrition Versus Subjective Global Assessment and Malnutrition Inflammation Score in Maintenance Hemodialysis Patients. , 2022, 32, 476-482.		17
172	Discriminative Impact of Ultrafiltration on Peritoneal Protein Transport. Peritoneal Dialysis International, 2000, 20, 39-46.	2.3	16
173	Hyaluronan Preserves Peritoneal Membrane Transport Properties. Peritoneal Dialysis International, 2001, 21, 136-143.	2.3	16
174	Major fractures after initiation of dialysis: Incidence, predictors and association with mortality. Bone, 2020, 133, 115242.	2.9	16
175	Simple Membrane Models for Peritoneal Dialysis. ASAIO Journal, 1992, 38, 788-796.	1.6	16
176	Nutritional Problems in Peritoneal Dialysis: An Overview. Peritoneal Dialysis International, 1999, 19, 297-303.	2.3	15
177	Variations in C-reactive protein during a single haemodialysis session do not associate with mortality. Nephrology Dialysis Transplantation, 2010, 25, 3717-3723.	0.7	15
178	Factors influencing access to education, decision making, and receipt of preferred dialysis modality in unplanned dialysis start patients. Patient Preference and Adherence, 2016, Volume 10, 2229-2237.	1.8	15
179	Model of fluid and solute shifts during hemodialysis with active transport of sodium and potassium. PLoS ONE, 2018, 13, e0209553.	2.5	15
180	Vitamin D deficiency and treatment versus risk of infection in end-stage renal disease patients under dialysis: a systematic review and meta-analysis. Nephrology Dialysis Transplantation, 2019, 34, 146-156.	0.7	15

#	Article	IF	Citations
181	Association of Serum Sclerostin with Bone Sclerostin in Chronic Kidney Disease is Lost in Glucocorticoid Treated Patients. Calcified Tissue International, 2019, 104, 214-223.	3.1	15
182	Mortality Predictive Role of Serum Uric Acid in Diabetic Hemodialysis Patients. , 2014, 24, 336-342.		14
183	Concomitant bidirectional transport during peritoneal dialysis can be explained by a structured interstitium. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 310, H1501-H1511.	3.2	14
184	A cohort study of insulin-like growth factor 1 and mortality in haemodialysis patients. CKJ: Clinical Kidney Journal, 2016, 9, 148-152.	2.9	14
185	Fractures and their sequelae in non-dialysis-dependent chronic kidney disease: the Stockholm CREAtinine Measurement project. Nephrology Dialysis Transplantation, 2020, 35, 1908-1915.	0.7	14
186	Functional vitamin K insufficiency, vascular calcification and mortality in advanced chronic kidney disease: A cohort study. PLoS ONE, 2021, 16, e0247623.	2.5	14
187	Bicarbonate-Based Peritoneal Dialysis Solution has Less Effect on Ingestive Behavior than Lactate-Based Peritoneal Dialysis Solution. Peritoneal Dialysis International, 2009, 29, 656-663.	2.3	13
188	An Increase of Plasma Advanced Oxidation Protein Products Levels Is Associated with Cardiovascular Risk in Incident Peritoneal Dialysis Patients: A Pilot Study. Oxidative Medicine and Cellular Longevity, 2015, 2015, 1-6.	4.0	13
189	Dietary Patterns of Patients with Chronic Kidney Disease: The Influence of Treatment Modality. Nutrients, 2019, 11, 1920.	4.1	13
190	High alkaline phosphatase and low intact parathyroid hormone associate with worse clinical outcome in peritoneal dialysis patients. Peritoneal Dialysis International, 2021, 41, 236-243.	2.3	13
191	Peritoneal Dialysis Solutions. Peritoneal Dialysis International, 2001, 21, 89-95.	2.3	12
192	Elevated Pro-Brain Natriuretic Peptide, Troponin T and Malnutrition Inflammatory Score in Chronic Hemodialysis Patients with Overt Cardiovascular Disease. Nephron Clinical Practice, 2011, 117, c198-c205.	2.3	12
193	Visceral Adipose Tissue and Leptin Hyperproduction Are Associated With Hypogonadism in Men With Chronic Kidney Disease. , 2017, 27, 243-248.		12
194	Inflammation down-regulates CYP3A4-catalysed drug metabolism in hemodialysis patients. BMC Pharmacology & Toxicology, 2018, 19, 33.	2.4	12
195	The value of the Brazilian aÃ§ai fruit as a therapeutic nutritional strategy for chronic kidney disease patients. International Urology and Nephrology, 2018, 50, 2207-2220.	1.4	12
196	Can nutritional interventions modulate the activation of the NLRP3 inflammasome in chronic kidney disease?. Food Research International, 2020, 136, 109306.	6.2	12
197	Peritoneal Dialysis Prescription for Diabetic Patients. Peritoneal Dialysis International, 2005, 25, 76-78.	2.3	11
198	Urinary albumin excretion, blood pressure changes and hypertension incidence in the community: effect modification by kidney function. Nephrology Dialysis Transplantation, 2014, 29, 1538-1545.	0.7	11

#	Article	IF	Citations
199	Elevated Circulating S100A12 Associates with Vascular Disease and Worse Clinical Outcome in Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2016, 36, 269-276.	2.3	11
200	Peritonitis: Episode Sequence, Microbiological Variation, Risk Factors and Clinical Outcomes in a North China Peritoneal Dialysis Center. Kidney and Blood Pressure Research, 2018, 43, 1573-1584.	2.0	11
201	Long Peritoneal Dialysis Dwells With Icodextrin: Kinetics of Transperitoneal Fluid and Polyglucose Transport. Frontiers in Physiology, 2019, 10, 1326.	2.8	11
202	Phosphate clearance in peritoneal dialysis. Scientific Reports, 2020, 10, 17504.	3.3	11
203	Transcapillary transport of water, small solutes and proteins during hemodialysis. Scientific Reports, 2020, 10, 18736.	3.3	11
204	Peritoneal dialysis patient selection from a comorbidity perspective. Seminars in Dialysis, 2022, 35, 25-39.	1.3	11
205	Rate of Synthetic Oligosaccharide Degradation as a Novel Measure of Amylase Activity in Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2008, 28, 296-304.	2.3	10
206	Timing of dialysis initiation and choice of dialysis modality. Nature Reviews Nephrology, 2011, 7, 66-68.	9.6	10
207	Delta-He: a novel marker of inflammation predicting mortality and ESA response in peritoneal dialysis patients. CKJ: Clinical Kidney Journal, 2014, 7, 275-281.	2.9	10
208	Renal function associates with energy intake in elderly community-dwelling men. British Journal of Nutrition, 2014, 111, 2184-2189.	2.3	10
209	Animal Models of Peritoneal Dialysis: Thirty Years of Our Own Experience. BioMed Research International, 2015, 2015, 1-9.	1.9	10
210	Serum hepatocyte growth factor is associated with truncal fat mass and increased mortality in chronic kidney disease stage 5 patients with protein-energy wasting. Nephrology Dialysis Transplantation, 2015, 30, 274-282.	0.7	10
211	Sensitivity and Specificity of Body Mass Index as a Marker of Obesity in Elderly Patients on Hemodialysis. , 2016, 26, 65-71.		10
212	Aortic Valve Calcium Associates with All-Cause Mortality Independent of Coronary Artery Calcium and Inflammation in Patients with End-Stage Renal Disease. Journal of Clinical Medicine, 2020, 9, 607.	2.4	10
213	Prognostic Value of Copeptin in Chronic Kidney Disease: From General Population to End-Stage Renal Disease. Current Protein and Peptide Science, 2017, 18, 1232-1243.	1.4	10
214	Muscle Mass Assessed by Computed Tomography at the Third Lumbar Vertebra Predicts Patient Survival in Chronic Kidney Disease. , 2021, 31, 342-350.		9
215	Copeptin is independently associated with vascular calcification in chronic kidney disease stage 5. BMC Nephrology, 2020, 21, 43.	1.8	9
216	Technique failure in remote patient monitoring program in patients undergoing automated peritoneal dialysis: A retrospective cohort study. Peritoneal Dialysis International, 2022, 42, 288-296.	2.3	9

#	Article	IF	Citations
217	Intraperitoneal Addition of Hyaluronan Improves Peritoneal Dialysis Efficiency. Peritoneal Dialysis International, 1999, 19, 106-111.	2.3	8
218	Ultrafiltration and Absorption in Evaluating Aquaporin Function from Peritoneal Transport of Sodium. Peritoneal Dialysis International, 2007, 27, 687-690.	2.3	8
219	Mathematical Modeling of the Glucose-Insulin System During Peritoneal Dialysis With Glucose-Based Fluids. ASAIO Journal, 2011, 57, 41-47.	1.6	8
220	Genotypic and phenotypic predictors of inflammation in patients with chronic kidney disease. Nephrology Dialysis Transplantation, 2016, 31, 2033-2040.	0.7	8
221	The importance of residual renal function in peritoneal dialysis. International Urology and Nephrology, 2016, 48, 2101-2108.	1.4	8
222	Bone mineral density of extremities is associated with coronary calcification and biopsy-verified vascular calcification in living-donor renal transplant recipients. Journal of Bone and Mineral Metabolism, 2017, 35, 536-543.	2.7	8
223	Plasma Beta-Trace Protein as a Marker of Residual Renal Function: The Effect of Different Hemodialysis Modalities and Intra-Individual Variability over Time. Kidney and Blood Pressure Research, 2017, 42, 877-885.	2.0	8
224	Changes of Peritoneal Transport Parameters with Time on Dialysis: Assessment with Sequential Peritoneal Equilibration Test. International Journal of Artificial Organs, 2017, 40, 595-601.	1.4	8
225	Dialysis Access, Infections, and Hospitalisations in Unplanned Dialysis Start Patients: Results from the Options Study. International Journal of Artificial Organs, 2017, 40, 48-59.	1.4	8
226	Could Low-Protein Diet Modulate Nrf2 Pathway in Chronic Kidney Disease?. , 2018, 28, 229-234.		8
227	Differences in association of lower bone mineral density with higher coronary calcification in female and male end-stage renal disease patients. BMC Nephrology, 2019, 20, 59.	1.8	8
228	Causes of death across categories of estimated glomerular filtration rate: The Stockholm CREAtinine Measurements (SCREAM) project. PLoS ONE, 2019, 14, e0209440.	2.5	8
229	Effects of acute fructose loading on levels of serum uric acidâ€”a pilot study. European Journal of Clinical Investigation, 2019, 49, e13040.	3.4	8
230	Association between Biomarkers of Mineral and Bone Metabolism and Removal of Calcium and Phosphate in Hemodialysis. Blood Purification, 2020, 49, 71-78.	1.8	8
231	Incidence of Fractures Before and After Dialysis Initiation. Journal of Bone and Mineral Research, 2020, 35, 2372-2380.	2.8	8
232	Association between reduced kidney function and incident hypoglycaemia in people with diabetes: The Stockholm <scp>Creatinine</scp> Measurements (<scp>SCREAM</scp>) project. Diabetes, Obesity and Metabolism, 2020, 22, 1425-1435.	4.4	8
233	Stopping versus continuing reninâ€“angiotensinâ€“system inhibitors after acute kidney injury and adverse clinical outcomes: an observational study from routine care data. CKJ: Clinical Kidney Journal, 2022, 15, 1109-1119.	2.9	8
234	Albuminâ€based Solutions for Peritoneal Dialysis: Investigations with a Rat Model. Artificial Organs, 1995, 19, 307-314.	1.9	7

#	Article	IF	Citations
235	The Effect of Icodextrin-Based Solutions on Peritoneal Transport in Rats Undergoing Chronic Peritoneal Dialysis. Peritoneal Dialysis International, 2001, 21, 359-361.	2.3	7
236	Albuminuria, renal dysfunction and circadian blood pressure rhythm in older men: a population-based longitudinal cohort study. CKJ: Clinical Kidney Journal, 2015, 8, 560-566.	2.9	7
237	Peritoneal Fluid Transport rather than Peritoneal Solute Transport Associates with Dialysis Vintage and Age of Peritoneal Dialysis Patients. Computational and Mathematical Methods in Medicine, 2016, 2016, 1-10.	1.3	7
238	Future Clinical Research with Icodextrin-Containing Solutions. Peritoneal Dialysis International, 1997, 17, 70-74.	2.3	6
239	Effect in a Rat Model of Heparinized Peritoneal Dialysis Catheters on Bacterial Colonization and the Healing of the Exit Site. Peritoneal Dialysis International, 2001, 21, 357-358.	2.3	6
240	Hyperhomocysteinemia, Malnutrition, and Inflammation in ESRD Patients. Seminars in Nephrology, 2006, 26, 14-19.	1.6	6
241	Uremic Toxicity. , 2013, , 49-77.		6
242	Dialysis Adequacy Indices and Body Composition in Male and Female Patients on Peritoneal Dialysis. Peritoneal Dialysis International, 2014, 34, 417-425.	2.3	6
243	Clinical determinants and prognostic significance of the electrocardiographic strain pattern in chronic kidney disease patients. Journal of the American Society of Hypertension, 2014, 8, 312-320.	2.3	6
244	Serum S100A12: A Risk Marker or Risk Factor of Vascular Calcification in Chronic Kidney Disease?. American Journal of Nephrology, 2015, 42, 1-3.	3.1	6
245	High blood glucose independent of pre-existing diabetic status predicts mortality in patients initiating peritoneal dialysis therapy. International Urology and Nephrology, 2015, 47, 1017-1024.	1.4	6
246	Sclerostinâ”€A Debutant on the Autosomal Dominant Polycystic Kidney Disease Scene?. Kidney International Reports, 2017, 2, 481-485.	0.8	6
247	Pregnancy-associated plasma protein-A predicts survival in end-stage renal diseaseâ€”confounding and modifying effects of cardiovascular disease, body composition and inflammation. Nephrology Dialysis Transplantation, 2018, 33, 971-977.	0.7	6
248	Sparing effect of peritoneal dialysis vs hemodialysis on BMD changes and its impact on mortality. Journal of Bone and Mineral Metabolism, 2021, 39, 260-269.	2.7	6
249	Fluid and Solute Transport using Different Sodium Concentrations in Peritoneal Dialysis Solutions. Peritoneal Dialysis International, 2001, 21, 1-8.	2.3	5
250	Circulating Alpha-Tocopherol and Insulin Sensitivity Among Older Men With Chronic Kidney Disease. , 2016, 26, 177-182.		5
251	La disminuciÃ³n de triyodotironina se asocia con la elevaciÃ³n del pÃ©ptido natriurÃ©tico cerebral N-terminal y con la mortalidad en pacientes en diÃ¡lisis. Nefrologia, 2017, 37, 598-607.	0.4	5
252	Monitoring relative blood volume changes during hemodialysis: Impact of the priming procedure. Artificial Organs, 2021, 45, 1189-1194.	1.9	5

#	Article	IF	Citations
253	Resistant Starch Type-2 Supplementation Does Not Decrease Trimethylamine N-Oxide (TMAO) Plasma Level in Hemodialysis Patients. , 2022, 41, 788-795.		5
254	Selection of Genetic and Phenotypic Features Associated with Inflammatory Status of Patients on Dialysis Using Relaxed Linear Separability Method. PLoS ONE, 2014, 9, e86630.	2.5	4
255	Phosphate Equilibration Rate and Daily Clearance in Patients on CAPD, CCPD and APD. International Journal of Artificial Organs, 2016, 39, 596-602.	1.4	4
256	Outcomes associated to serum phosphate levels in patients with suspected acute coronary syndrome. International Journal of Cardiology, 2017, 245, 20-26.	1.7	4
257	What pd Research in China Tells Us. Peritoneal Dialysis International, 2018, 38, 19-24.	2.3	4
258	Association between reduced renal function and cardiovascular mortality in patients hospitalized with infection: A multi-center cohort study. European Journal of Internal Medicine, 2018, 57, 32-38.	2.2	4
259	Design and methodology of the Aging Nephropathy Study (AGNES): a prospective cohort study of elderly patients with chronic kidney disease. BMC Nephrology, 2020, 21, 461.	1.8	4
260	Secular trends in hip fracture incidence and subsequent mortality in dialysis patients and the general population in Sweden. Bone, 2021, 147, 115909.	2.9	4
261	Water removal during automated peritoneal dialysis assessed by remote patient monitoring and modelling of peritoneal tissue hydration. Scientific Reports, 2021, 11, 15589.	3.3	4
262	Improved plasma amino acids pattern following 12 months of supplemented low-protein diet in peritoneal dialysis patients. Renal Failure, 2010, 32, 709-715.	2.1	3
263	Comparison of three PET methods to assess peritoneal membrane transport. Brazilian Journal of Medical and Biological Research, 2019, 52, e8596.	1.5	3
264	Burden and causes of hospital admissions and readmissions in patients undergoing hemodialysis and peritoneal dialysis: a nationwide study. Journal of Nephrology, 2021, 34, 1949-1959.	2.0	3
265	Treatment practices and outcomes in incident peritoneal dialysis patients: the Swedish Renal Registry 2006â€“2015. CKJ: Clinical Kidney Journal, 2021, 14, 2539-2547.	2.9	3
266	Association between implementation of novel therapies and improved survival in patients starting haemodialysis: the Swedish Renal Registry 2006â€“15. Nephrology Dialysis Transplantation, 2021, 36, 1298-1306.	0.7	3
267	A Simple and Fast Method to Estimate Peritoneal Membrane Transport Characteristics Using Dialysate Sodium Concentration. Peritoneal Dialysis International, 1999, 19, 212-216.	2.3	2
268	Mechanisms and clinical implications of lipid disorders in chronic kidney disease. Clinical Lipidology, 2009, 4, 449-456.	0.4	2
269	Reducing insulin resistance in patients undergoing peritoneal dialysis through the use of icodextrin-based solutions. Nephrology Dialysis Transplantation, 2015, 30, 1783-1785.	0.7	2
270	Do metabolic derangements in endâ€stage polycystic kidney disease differ versus other primary kidney diseases?. Nephrology, 2018, 23, 31-36.	1.6	2

#	Article	IF	Citations
271	Dialysate copeptin and peritoneal transport in incident peritoneal dialysis patients. International Urology and Nephrology, 2019, 51, 1667-1673.	1.4	2
272	Inter-leg systolic blood pressure difference predicts cardiovascular events and mortality in incident hemodialysis patients. International Journal of Artificial Organs, 2020, 43, 217-224.	1.4	2
273	On the change of transport parameters with dwell time during peritoneal dialysis. Peritoneal Dialysis International, 2021, 41, 404-412.	2.3	2
274	Author Response: Kidney Function, Kidney Function Decline, and the Risk of Dementia in Older Adults. Neurology, 2021, 97, 967-967.	1.1	2
275	Dialysis Outcomes in a Middle-Income Country: An Updated Comparison of Patient Mortality between Hemodialysis and Peritoneal Dialysis. Blood Purification, 2022, 51, 780-790.	1.8	2
276	The role of N-terminal pro-brain natriuretic peptide (NT-pro-BNP) as a prognostic marker in older people: the impact of reduced renal function. Reviews in Clinical Gerontology, 2009, 19, 71-76.	0.5	1
277	P1389MAJOR OSTEOPOROTIC FRACTURES AFTER INITIATION OF DIALYSIS: INCIDENCE, PREDICTORS AND ASSOCIATION WITH MORTALITY. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	1
278	FP344LEFT ATRIAL VOLUME AND MORTALITY AMONG PATIENTS WITH CHRONIC KIDNEY DISEASE STAGES 3-5. Nephrology Dialysis Transplantation, 2015, 30, iii183-iii183.	0.7	0
279	SP242GLOMERULAR FILTRATION RATE ESTIMATION USING BETA TRACE PROTEIN: EXTERNAL VALIDATION OF THREE EQUATIONS. Nephrology Dialysis Transplantation, 2016, 31, i167-i167.	0.7	0
280	SP286PLASMA BETA TRACE PROTEIN PREDICTS MORTALITY IN CKD: RELATION WITH ENDOTHELIAL DYSFUNCTION. Nephrology Dialysis Transplantation, 2016, 31, i183-i184.	0.7	0
281	SP296THYROID FUNCTIONAL DISORDERS ASSOCIATED WITH MORTALITY IN CHRONIC KIDNEY DISEASE: ASYSTEMATIC REVIEW AND META-ANALYSIS. Nephrology Dialysis Transplantation, 2016, 31, i187-i188.	0.7	0
282	SP621POOR PROGNOSIS LINKED TO REDUCED MUSCLE MASS IN HEMODIALYSIS PATIENTS IS MAINLY CONFINED TO ELDERLY MEN. Nephrology Dialysis Transplantation, 2016, 31, i302-i302.	0.7	0
283	In Memoriam. Peritoneal Dialysis International, 2016, 36, 5-6.	2.3	0
284	MP713PREDICTIVE FACTORS OF ANEMIA WITHIN 1 YEAR AFTER LIVING DONOR KIDNEY TRANSPLANTATION. Nephrology Dialysis Transplantation, 2016, 31, i576-i576.	0.7	0
285	SP298HIGHER MEAN CORPUSCULAR VOLUME ASSOCIATES WITH POOR CLINICAL OUTCOME IN CKD5 PATIENTS. Nephrology Dialysis Transplantation, 2018, 33, i444-i444.	0.7	0
286	FP336HIGHER NEUTROPHIL TO LYMPHOCYTE RATIO ASSOCIATES WITH POOR CLINICAL OUTCOME IN CKD5 PATIENTS. Nephrology Dialysis Transplantation, 2018, 33, i144-i145.	0.7	0
287	SP330AEGFR AND THE RISK OF CANCER: THE STOCKHOLM CREATININE MEASUREMENTS (SCREAM) PROJECT. Nephrology Dialysis Transplantation, 2018, 33, i455-i455.	0.7	0
288	SP323HIGH FIBRINOGEN LEVELS ARE INDEPENDENTLY ASSOCIATED WITH INCREASED MORTALITY IN PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD). Nephrology Dialysis Transplantation, 2018, 33, i452-i452.	0.7	0

#	Article	IF	Citations
289	FP435MODELING POTASSIUM BEHAVIOUR DURING HAEMODIALYSIS UNDER DIFFERENT TREATMENT CONDITIONS. Nephrology Dialysis Transplantation, 2018, 33, i181-i181.	0.7	0
290	P1409HIP FRACTURE TRENDS IN SWEDISH GENERAL POPULATION AND DIALYSIS PATIENTS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
291	P1448FACTORS ASSOCIATED WITH INCREASED MORTALITY AFTER DIALYSIS INITIATION. RESULTS OF THE PERIDIALYSIS STUDY. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
292	P1415PARATHYROIDECTOMY IMPROVES MUSCULAR FUNCTION BUT NOT MUSCLE MASS IN HEMODIALYSIS PATIENTS WITH SEVERE HYPERPARATHYROIDISM. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
293	P0673INVERSE ASSOCIATION OF TRANSFERRIN SATURATION WITH MORTALITY RISK IN CHRONIC KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
294	P0791MATRIX GLA PROTEIN AND PREMATURE VASCULAR CALCIFICATION IN PATIENTS WITH END-STAGE RENAL DISEASE. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
295	P1137FACTORS DETERMINING CHOICE OF DIALYSISI MODALITY AMONG PATIENTS INITIATING DIALYSIS. RESULTS OF THE PERIDIALYSIS STUDY. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
296	P1158DOES THE PERITONEUM SWELLS OR SHRINK DURING PERITONEAL DIALYSIS?. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
297	MO576ASSOCIATION OF BONE MATERIAL STRENGTH WITH BONE DENSITY IN PATIENTS WITH END-STAGE RENAL DISEASE. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
298	MO678DISTRIBUTION OF PERIPHERAL BLOOD T CELL SUBTYPESÂIN HEMODIALYSIS PATIENTS TREATED WITH MEDIUM CUT-OFF MEMBRANES AND HIGH-FLUXÂMEMBRANES. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
299	MO703URINE VOLUME AS A MARKER OF RESIDUAL KIDNEY FUNCTION IN PERITONEAL DIALYSIS PATIENTS: QUANTITATIVE ASSESSMENT. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
300	Cardiovascular Disease and Inflammation. , 2021, , 1-22.		0
301	Protein-Energy Wasting/Malnutrition and the Inflammatory Response. , 2020, , 413-429.		0
302	KT/V: the denominator dilemma. Polski Merkuriusz Lekarski, 2003, 15, 311-5.	0.3	0
303	MO560: Adherence to Nutritional Recommendations as Expressed by Patients on Hemodialysis, Their Informal Carers and Healthcare Professionalsâ€"the Goodrenal Project. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
304	MO673: Association of Mean Corpuscular Volume with Mortality in Kidney Failure Patients: Opposite Findings in Chinese and Swedish Kidney Failure Patients. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
305	FC 129: Stopping versus Continuing Reninâ€"Angiotensin System Inhibitors After Acute Kidney Injury and Adverse Clinical Outcomes: An Observational Study From Routine Care Data. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
306	MO708: Association ofÂAtherogenicÂIndexÂof Plasma (AIP) with Mortality in Chinese and Swedish End-StageÂKidneyÂDisease Patients: Results from Two Cohorts. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0

#	Article	IF	Citations
307	MO917: Self-Reported Perceptions of Haemodialysis PatientsÂ´ Cognitive Stateâ€“â€“The Goodrenal Project. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
308	MO925: Psychological Wellbeing in Haemodialysis Patients: Comparing Perspectives From Patients, Caregivers and Healthcare Professionalsâ€“â€“The Goodrenal Project. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
309	MO681: Association of Framingham Risk Score with Mortality in Kidney Failure Patients from China and Sweden. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0